SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Shanghai, China.
SMO ClinPlus Co. Ltd. (301257) - Net Assets
Latest net assets as of June 2025: CN¥1.22 Billion CNY
Based on the latest financial reports, SMO ClinPlus Co. Ltd. (301257) has net assets worth CN¥1.22 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.47 Billion) and total liabilities (CN¥247.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.22 Billion |
| % of Total Assets | 83.11% |
| Annual Growth Rate | 56.41% |
| 5-Year Change | 611.18% |
| 10-Year Change | N/A |
| Growth Volatility | 117.67 |
SMO ClinPlus Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how SMO ClinPlus Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SMO ClinPlus Co. Ltd. (2019–2024)
The table below shows the annual net assets of SMO ClinPlus Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | +8.56% |
| 2023-12-31 | CN¥1.08 Billion | +13.51% |
| 2022-12-31 | CN¥951.97 Million | +315.99% |
| 2021-12-31 | CN¥228.84 Million | +38.73% |
| 2020-12-31 | CN¥164.96 Million | +31.76% |
| 2019-12-31 | CN¥125.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SMO ClinPlus Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 543.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥407.21 Million | 34.71% |
| Other Components | CN¥765.93 Million | 65.29% |
| Total Equity | CN¥1.17 Billion | 100.00% |
SMO ClinPlus Co. Ltd. Competitors by Market Cap
The table below lists competitors of SMO ClinPlus Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Semler Scientific Inc
NASDAQ:SMLR
|
$348.27 Million |
|
OPUS GLOBAL Nyrt
BUD:OPUS
|
$348.36 Million |
|
SK Networks Co Ltd
KO:001740
|
$348.44 Million |
|
Marcus Corporation
NYSE:MCS
|
$348.48 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
$347.95 Million |
|
ThredUp Inc
NASDAQ:TDUP
|
$347.81 Million |
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
$347.71 Million |
|
ZEAL Network SE
XETRA:TIMA
|
$347.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SMO ClinPlus Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,080,595,266 to 1,173,140,831, a change of 92,545,564 (8.6%).
- Net income of 106,429,303 contributed positively to equity growth.
- Dividend payments of 22,078,760 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥106.43 Million | +9.07% |
| Dividends Paid | CN¥22.08 Million | -1.88% |
| Other Changes | CN¥8.20 Million | +0.7% |
| Total Change | CN¥- | 8.56% |
Book Value vs Market Value Analysis
This analysis compares SMO ClinPlus Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.88x to 3.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥2.78 | CN¥55.31 | x |
| 2020-12-31 | CN¥2.82 | CN¥55.31 | x |
| 2021-12-31 | CN¥3.91 | CN¥55.31 | x |
| 2022-12-31 | CN¥12.01 | CN¥55.31 | x |
| 2023-12-31 | CN¥13.59 | CN¥55.31 | x |
| 2024-12-31 | CN¥14.76 | CN¥55.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SMO ClinPlus Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.24%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.22x
- Recent ROE (9.07%) is below the historical average (19.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 41.82% | 17.25% | 1.50x | 1.61x | CN¥39.84 Million |
| 2020 | 21.41% | 10.53% | 1.15x | 1.77x | CN¥18.82 Million |
| 2021 | 25.24% | 11.49% | 1.24x | 1.77x | CN¥34.88 Million |
| 2022 | 7.61% | 12.35% | 0.51x | 1.22x | CN¥-22.79 Million |
| 2023 | 12.47% | 17.73% | 0.56x | 1.26x | CN¥26.67 Million |
| 2024 | 9.07% | 13.24% | 0.56x | 1.22x | CN¥-10.88 Million |
Industry Comparison
This section compares SMO ClinPlus Co. Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,954,475,258
- Average return on equity (ROE) among peers: 5.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SMO ClinPlus Co. Ltd. (301257) | CN¥1.22 Billion | 41.82% | 0.20x | $347.98 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |